Products for Research Use Only

Emtricitabine-d2

CAT: 0804-HY-17427S4Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17427S4Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Emtricitabine-d2 (BW1592-d2) is deuterium labeled Emtricitabine. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.
Product Name Alternative
BW1592-d2
UNSPSC
12352005
Target
Endogenous Metabolite; HIV; Isotope-Labeled Compounds; Reverse Transcriptase
Related Pathways
Anti-infection; Metabolic Enzyme/Protease; Others
Applications
COVID-19-anti-virus
Field of Research
Infection
Smiles
O=C1N(C=C(C(N)=N1)F)[C@H]2O[C@H](SC2)C([2H])([2H])O
Molecular Formula
C8H8D2FN3O3S
Molecular Weight
249.26
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Faltz M, et al. Effect of the Anti-retroviral Drugs Efavirenz, Tenofovir and Emtricitabine on Endothelial Cell Function: Role of PARP. Cardiovasc Toxicol. 2017 Jan 3. [Epub ahead of print]|[3]Saag MS, et al. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin Infect Dis.?2006 Jan 1;42 (1) :126-31.|[4]Szczech GM, Wang LH, Walsh JP, Reproductive toxicology profile of emtricitabine in mice and rabbits. Reprod Toxicol. 2003 Jan-Feb;17 (1) :95-108.|[5]Xu P, et al. Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation In Vivo and In Vitro. J Neuroimmune Pharmacol. 2017 Dec;12 (4) :682-692.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported